Agenus (NASDAQ:AGEN) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.
AGEN has been the topic of several other reports. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Tuesday, January 9th. ValuEngine upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $5.81.
Shares of AGEN opened at $4.46 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of -1.88. Agenus has a 52 week low of $3.20 and a 52 week high of $6.19. The company has a market capitalization of $457.40, a PE ratio of -3.63 and a beta of 1.66.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $5.30 million. The company’s revenue was up 48.2% compared to the same quarter last year. analysts forecast that Agenus will post -1.52 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of AGEN. MetLife Investment Advisors LLC purchased a new stake in shares of Agenus in the 4th quarter worth $124,000. Raymond James & Associates purchased a new stake in shares of Agenus in the 4th quarter worth $130,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Agenus in the 3rd quarter worth $134,000. North Star Asset Management Inc. purchased a new stake in shares of Agenus in the 4th quarter worth $222,000. Finally, Highbridge Capital Management LLC increased its stake in shares of Agenus by 242.8% in the 3rd quarter. Highbridge Capital Management LLC now owns 56,642 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 40,118 shares in the last quarter. Hedge funds and other institutional investors own 36.46% of the company’s stock.
WARNING: “BidaskClub Downgrades Agenus (AGEN) to Strong Sell” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/09/bidaskclub-downgrades-agenus-agen-to-strong-sell.html.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.